Skip to content

Study · Animal study (in vivo) · mouse · 2002

2 results

Epithalon inhibits tumor growth and expression of HER-2/neu oncogene in breast tumors in transgenic mice characterized by accelerated aging.

Anisimov VN, Khavinsov VKh, Alimova IN, Provintsiali M, Manchini R, Francheski K

Bulletin of experimental biology and medicine1 Feb 2002Cited by 4 (Europe PMC)

PMID12428286 (opens in a new tab)DOI10.1023/a:1015555023692 (opens in a new tab)PepBankPUB-12428286
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In HER-2/neu transgenic mice, the maximum size of breast adenocarcinomas was 33% lower with Epithalon than in the control.

    In plain wordsIn mice prone to breast cancer, Epithalon made the largest tumors smaller than in the control group.

    Peptide
    Epitalon
    Outcome
    DecreaseMaximum size of breast adenocarcinomas
    Study

    mousen: not reported in source

    HER-2/neu transgenic FVB mice
    Comparator
    Control
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 microgram · subcutaneousAs given in this study (mouse).

    Measurements

    Reduction in maximum tumor size
    33%
    Epithalon vs control

    Source sentences

    Summary
    Epithalon markedly inhibited neoplasm development: the maximum size of breast adenocarcinomas was 33% lower than in the control (p < 0.05).
    1 context sentence
    Summary · context
    Female transgenic FVB mice carrying breast cancer gene HER-2/neu were monthly injected with Vilon or Epithalon (1 microgram subcutaneously for 5 consecutive days) starting from the 2nd month of life.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In HER-2/neu transgenic mice, HER-2/neu mRNA expression in breast tumors was 3.7 times lower with Epithalon than in control animals.

    In plain wordsIn mice prone to breast cancer, Epithalon lowered HER-2/neu gene activity in tumors compared with control animals.

    Peptide
    Epitalon
    Outcome
    DecreaseHER-2/neu mRNA expression in breast tumors
    Study

    mousen: not reported in source

    HER-2/neu transgenic FVB mice
    Comparator
    Control
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    1 microgram · subcutaneousAs given in this study (mouse).

    Measurements

    HER-2/neu mRNA reduction
    3.7 times
    Epithalon vs control

    Source sentences

    Summary
    The intensity of HER-2/neu mRNA expression in breast tumors of Epithalon-treated mice was 3.7 times lower than in control animals.
    1 context sentence
    Summary · context
    Female transgenic FVB mice carrying breast cancer gene HER-2/neu were monthly injected with Vilon or Epithalon (1 microgram subcutaneously for 5 consecutive days) starting from the 2nd month of life.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.